<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183166</url>
  </required_header>
  <id_info>
    <org_study_id>TG4050.02</org_study_id>
    <nct_id>NCT04183166</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating TG4050 in Head and Neck Cancer</brief_title>
  <official_title>A Randomized Phase I Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, two arms, randomized, phase I study evaluating the safety
      and tolerability as well as some activity parameters of TG4050 in patients with squamous cell
      carcinoma of the head and neck (SCCHN).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Adverse Event reported per CTCAE v5)</measure>
    <time_frame>Up to 2 Years.</time_frame>
    <description>Incidence of Adverse Event reported per CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival duration</measure>
    <time_frame>Up to 2 Years.</time_frame>
    <description>Time from documented Complete Response after primary treatment to date of first recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to RECIST version 1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A : Early study treatment initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG4050 treatment initiation at completion of primary treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Study treatment initiation at recurrence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG4050 treatment initiation at the time of recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG4050</intervention_name>
    <description>Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks</description>
    <arm_group_label>Arm A : Early study treatment initiation</arm_group_label>
    <arm_group_label>Arm B: Study treatment initiation at recurrence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Newly diagnosed stage III or IVA squamous-cell carcinoma of the oral cavity,
             oropharynx, hypopharynx or larynx

          3. Female or male patients, aged at least 18 years

          4. Patients in Complete Response after treatment of their primary tumor.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

          6. Adequate hematological, hepatic and renal functions

        Exclusion Criteria:

          1. Patients with carcinoma of the nasopharynx, squamous cell-carcinoma of unknown
             primary, squamous cell carcinoma that originates from the skin and salivary gland or
             paranasal sinus, non-squamous histologies.

          2. Prior exposure to cancer immunotherapy including anti-cancer vaccines, any antibody
             targeting T-cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA4
             antibodies.

          3. Other active malignancy requiring concurrent systemic intervention.

          4. Patients with previous malignancies other than the target malignancy to be
             investigated in this trial

          5. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known
             Acquired Immune Deficiency Syndrome (AIDS)

          6. Clinical or laboratory history or evidence of Hepatitis C Virus (HCV) or Hepatitis B
             Virus (HBV) indicating acute or chronic infection

          7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (&gt; 10 mIU/mL)

          8. Treatment with another investigational agent within 30 days prior to TG4050 treatment
             initiation

          9. Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Transgene EU, Clinical Operations Department</last_name>
    <phone>+ 33.3.88.27.91.00</phone>
    <email>clinical.trials@transgene.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital NHS Fondation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal mardsen NHS Fondation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital NHS Fondation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

